American Journal of Epidemiology Advance Access published online on December 22, 2005
American Journal of Epidemiology, doi:10.1093/aje/kwj027
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Mathematics, University of California Los Angeles, Los Angeles, CA; Department of Statistics, University of California Los Angeles, Los Angeles, CA
* To whom correspondence should be addressed. Using the Framingham Heart Study data (United States, 1948-1978), the authors examined the association of blood glucose with 2-year all-cause, cardiovascular, and noncardiovascular mortality in subjects with documented cardiovascular disease. After adjustment for systolic blood pressure, cholesterol, body mass index, cigarette smoking, and use of antihypertensive agents, they found that glucose was a strong, independent predictor of mortality. However, the relations for men and women were qualitatively different. For men, adjusted mortality risk increased very rapidly through the normal range (from 4.12% at 3.89 mmol/liter (70 mg/dl) to 12.26% at 5.55 mmol/liter (100 mg/dl)) and was flat at 12.26% thereafter. For women, risk was flat at 3.65% through the normal range and then increased rapidly, reaching 8.34% at 6.99 mmol/liter (126 mg/d), but increased much more slowly thereafter. Exactly analogous relations held for cardiovascular mortality. For men and women combined, noncardiovascular mortality increased from 1.82% at 3.89 mmol/liter to 2.06% at 5.55 mmol/liter to 2.29% at 6.99 mmol/liter (p for trend = 0.009). These findings suggest that although 5.55 mmol/liter (normal) may be a useful mortality risk division (albeit with different implications for the two sexes), 6.99 mmol/liter (diabetic) is not, especially for men.
Received April 2, 2005
Accepted September 2, 2005
ORIGINAL CONTRIBUTIONS
The Predictive Role of Blood Glucose for Mortality in Subjects with Cardiovascular Disease
Sidney C. Port 1 *,
Noel G. Boyle 2,
Willa A. Hsueh 3,
Manuel J. Quiñones 3,
Robert I. Jennrich 4,
and
Mark O. Goodarzi 5
2 Division of Cardiology, UCLA Medical Center, Los Angeles, CA
3 Division of Endocrinology, Diabetes, and Hypertension, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
4 Department of Statistics, University of California Los Angeles, Los Angeles, CA
5 Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA
Sidney C. Port, E-mail: sport{at}ucla.edu
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. O. Goodarzi and B. M. Psaty Glucose Lowering to Control Macrovascular Disease in Type 2 Diabetes: Treating the Wrong Surrogate End Point? JAMA, November 5, 2008; 300(17): 2051 - 2053. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Kulminski, S. V. Ukraintseva, I. V. Culminskaya, K. G. Arbeev, K. C. Land, L. Akushevich, and A. I. Yashin Cumulative Deficits and Physiological Indices as Predictors of Mortality and Long Life J Gerontol A Biol Sci Med Sci, October 1, 2008; 63(10): 1053 - 1059. [Abstract] [Full Text] [PDF]
|
|